Peripheral Artery Disease (Claudication, Investigational)
Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for peripheral artery disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for PAD is highly investigational.
- Какие доказательства существуют?
- Tier C (highly investigational). A handful of small uncontrolled case reports describe walking-distance improvement; there are no randomized controlled trials and no data on amputation, MI, or stroke prevention. Evidence-based PAD care per AHA/ACC 2016 guidelines includes smoking cessation, statin therapy, antiplatelet medication (aspirin or clopidogrel), structured supervised exercise (the strongest evidence for claudication), and revascularization (angioplasty / bypass) for lifestyle-limiting disease or critical limb ischemia. Leech therapy on a leg with poor arterial flow can cause tissue breakdown.
- Основные риски
- Tissue breakdown, non-healing wound, or gangrene if applied to a limb with low ABI (under 0.6) — this is the dominant risk
- Bleeding from bite sites for 6 to 24 hours after detachment
- Local skin infection or, rarely, Aeromonas infection
- Worsening anemia from cumulative blood loss
- Allergic reaction to leech saliva (uncommon)
- Bleeding interaction with antiplatelet medications (aspirin, clopidogrel) — usually required for PAD
- Delay or replacement of evidence-based therapy with risk of amputation, MI, or stroke
- Кому не следует это рассматривать
- Patients with ABI under 0.6 (critical limb ischemia)
- Patients on antiplatelet therapy (aspirin, clopidogrel) — required for most PAD patients
- Patients with a diabetic foot ulcer or active gangrene
- Patients within 6 weeks of vascular intervention (angioplasty, stenting, bypass)
- Patients with rest pain or non-healing wounds (urgent vascular surgery indication)
- Patients with active infection, hemophilia, or severe anemia
- О чём спросить врача
- What is my ankle-brachial index (ABI) and toe-brachial index, and what is my Rutherford / Fontaine class?
- Am I on a statin and appropriate antiplatelet therapy?
- Have I tried supervised exercise therapy — the highest-evidence intervention for claudication?
- Am I a candidate for revascularization (angioplasty, stent, bypass)?
- What is my vascular surgery team's opinion on adjunctive complementary therapy?
- If antiplatelet must continue, is leech therapy compatible at all?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Когда срочно обратиться за медицинской помощью
- Sudden severe leg pain, coldness, pallor, or pulselessness (acute limb ischemia — call 911)
- Rest pain that interferes with sleep, or a non-healing leg or foot wound
- New gangrene, blackening, or ulceration
- Chest pain, pressure, or shortness of breath
- Sudden weakness, slurred speech, facial droop, or vision loss
- Bleeding from a bite site lasting more than 24 to 48 hours, fever, spreading redness, or pus
- Hives, throat tightness, or breathing difficulty
Что это НЕ означает
- This is not FDA-cleared for peripheral artery disease.
- Small uncontrolled reports do NOT establish efficacy on walking distance vs. supervised exercise or on cardiovascular outcomes.
- Mechanism rationale (microvascular flow) does NOT fix proximal arterial stenosis.
- Leech therapy is NEVER a substitute for supervised exercise, statin / antiplatelet therapy, or revascularization when indicated.
- Critical limb ischemia requires urgent vascular surgical evaluation, NOT complementary therapy.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- cardiovascular
- ICD-10
- I70.211, I70.212, I70.213, I73.9
- Safety tier
- high
Evidence Summary
Peripheral artery disease management follows AHA/ACC guidelines: smoking cessation, statin and antiplatelet therapy, supervised exercise, and revascularization for lifestyle-limiting claudication or critical limb ischemia. No controlled trial or case series of hirudotherapy for PAD or claudication has been published; use for this indication is investigational and mechanistic only. Critical safety: leech application to a limb with an ankle-brachial index <0.6 risks tissue breakdown and gangrene, and most PAD patients require antiplatelet therapy, which is an exclusion for leech application.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Andereya S et al. (2008), n=18
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- ABI <0.6 (critical limb ischemia)
- Antiplatelet therapy (aspirin, clopidogrel) — absolute exclusion
- Diabetic foot ulcer or active gangrene
- Recent vascular intervention (<6 weeks)
- Concurrent statin-related rhabdomyolysis
Related Conditions
Essential Hypertension (Adjunctive)
Investigational adjunctive use; mechanism includes mild diuresis from blood-volume removal and hirudin-mediated vascular endothelial effects. Not a substitute for pharmacotherapy.
Atrial Fibrillation (Adjunctive Investigational)
Highly investigational adjunct for paroxysmal atrial fibrillation; no controlled trials; conventional anticoagulation and rate/rhythm control remain primary.
Congestive Heart Failure (Compensated, Investigational Adjunct)
Investigational adjunct in compensated NYHA II heart failure; no RCT support; guideline-directed medical therapy remains primary.